TORONTO, Ontario – Medlantis announced today a partnership with Japanese medical device corporation Terumo. Together they will create a global, internal training program focusing specifically on hepatocellular carcinoma (HCC), a primary malignancy of the liver.
The main goal is to standardize comprehension of the disease and procedure on a global scale for sales representatives, as well as have a digital process in place that can keep up with ever-changing technology and education. Both are becoming vital directives for international companies in every industry.
“It is no longer feasible to generate sales training per region, and have that manageable at a global level when so many digital solutions can be utilized that not only save time and money, but can standardize the training process worldwide.” Andrew Witchell, VP Product Development and Marketing
With a wide array of Terumo’s devices supporting interventional oncology (IO), as well as hepatocellular carcinoma procedures and treatments, the partnership with Medlantis to develop an e-learning training program has come at the right time.
“This is the first, global initiative that we have undertaken for Terumo Interventional Systems. One of the biggest risks from a corporate perspective is global inconsistency of training. In a face-to-face environment, there is no way for companies to ensure that a sales rep in one region of the world is receiving the same quality of training and preparation for their sales that another rep in another part of the world has. And that has a direct affect on sales revenue.”
Steve Dubrick, VP Education at Medlantis.
Medlantis will work with subject matter experts around the world to identify the key learning objectives, as well as update the content in real-time as education changes and grows. The training program is targeted for several international regions including: Europe, the United States, Latin America, China, Japan, and India. It will be available in English, Japanese, simplified Mandarin, and Latin-American Spanish.